Get the Stockscreener App
5.43
2.34%
-0.13
After Hours:
5.42
-0.010
-0.18%
Cytomx Therapeutics Inc stock is traded at $5.43, with a volume of 1.85M.
It is down -2.34% in the last 24 hours and up +25.12% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$5.56
Open:
$5.54
24h Volume:
1.85M
Relative Volume:
0.59
Market Cap:
$920.03M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-271.50
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
+3.63%
1M Performance:
+25.12%
6M Performance:
+191.94%
1Y Performance:
+583.45%
1-Day Range:
$5.35
$5.5583
1-Week Range:
$5.195
$5.995
52-Week Range:
$0.40
$6.35
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
5.43 | 942.06M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts - MarketBeat
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares - GuruFocus
CytomX at Guggenheim Summit: Promising CRC Treatment Path By Investing.com - Investing.com Canada
Stock Recap: Is CytomX Therapeutics Inc benefiting from interest rate changes2025 Institutional Moves & Capital Protection Trade Alerts - baoquankhu1.vn
How New Analyst Assumptions Are Rewriting The Story For CytomX Therapeutics (CTMX) - Yahoo Finance
Rally Mode: Can CytomX Therapeutics Inc navigate macro headwindsJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: Exploring a 58.73% Potential Upside Amid Innovative Oncology Developments - DirectorsTalk Interviews
Analysis Recap: Whats the profit margin of CytomX Therapeutics IncWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
CytomX Therapeutics (CTMX) Price Target Increased by 20.20% to 8.67 - Nasdaq
Cantor Fitzgerald Raises Price Target for CytomX Therapeutics (C - GuruFocus
Cantor Fitzgerald Raises CytomX Therapeutics (NASDAQ:CTMX) Price Target to $10.00 - MarketBeat
CTMX: Barclays Analyst Raises Price Target to $10.00 | CTMX Stock News - GuruFocus
CytomX Therapeutics to Present at Upcoming February Conferences - 富途牛牛
CytomX Therapeutics price target raised to $10 from $8 at Barclays - TipRanks
A Look At CytomX Therapeutics (CTMX) Valuation After Optimistic Analyst Target Hikes On Phase 1 Cancer Data - Sahm
CytomX Therapeutics stock hits 52-week high at 6.16 USD By Investing.com - Investing.com Nigeria
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
CytomX Therapeutics stock hits 52-week high at 6.16 USD - Investing.com
CytomX Therapeutics (CTMX) Is Up 14.0% After Early Probody Colorectal Cancer Data Are Welcomed By Analysts – Has The Bull Case Changed? - Yahoo Finance
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Insider Monkey
Can CytomX Therapeutics Inc. disrupt its industryProfit Target & Consistent Growth Equity Picks - mfd.ru
CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Biotech Innovator with 44% Potential Upside - DirectorsTalk Interviews
Will CytomX Therapeutics Inc. benefit from AI trendsRate Hike & Daily Volume Surge Signals - mfd.ru
What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You - simplywall.st
CytomX stock rises 31% in a month: Here's what you should know - MSN
Fed Watch: What is CytomX Therapeutics Incs TAM Total Addressable MarketMarket Sentiment Summary & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Is CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st
Forecast Cut: Does RAPT Therapeutics Inc stock benefit from AI growthJuly 2025 Closing Moves & Low Risk High Reward Trade Ideas - baoquankhu1.vn
CytomX Therapeutics (NASDAQ:CTMX) Sets New 1-Year HighShould You Buy? - MarketBeat
Patterns Watch: Is CytomX Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & AI Driven Stock Price Forecasts - baoquankhu1.vn
CytomX Therapeutics (NASDAQ:CTMX) Shares Down 5.3%Here's Why - MarketBeat
Guggenheim Upgrades CytomX Therapeutics (NASDAQ:CTMX) to "Strong-Buy" - MarketBeat
Piper Sandler raises CytomX Therapeutics stock price target to $10 on cancer drug data - Investing.com Canada
CTMX: Barclays Raises Price Target from $6.00 to $8.00, Maintains Overweight Rating | CTMX Stock News - GuruFocus
Guggenheim Initiates Coverage of CytomX Therapeutics (CTMX) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on CytomX Therapeutics (CTMX) with 'Buy' Rating | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Receives Target Price Upgrade from Pi - GuruFocus
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Formidable Asset Management LLC Sells 194,513 Shares of CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Stock Rises 31% in a Month: Here's What You Should Know - Yahoo Finance
Risk Analysis: What is LILAKs book value per shareGDP Growth & AI Powered Trade Plan Recommendations - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected - 富途资讯
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 12-Month HighHere's What Happened - MarketBeat
CytomX Therapeutics' (NASDAQ:CTMX) investors will be pleased with their incredible 402% return over the last year - Yahoo Finance
CTMX Stock Price, Forecast & Analysis | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - Chartmill
Volatility Watch: Does CytomX Therapeutics Inc have strong EBITDA margins2025 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
CTMX: Vaseta M and CX801 advance in clinical trials, targeting major unmet needs in oncology - TradingView
Is CytomX Therapeutics Inc stock heavily shortedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Drugmaker signed East Bay's biggest Q4 lease, moving away from South San Francisco - The Business Journals
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):